Human Papillomavirus Vaccine: A New Chance to Prevent Cervical Cancer
Human papillomavirus (HPV) is a significant source of morbidity and mortality throughout the world and is the most common sexually transmitted infection in the United States. HPV is the primary etiologic agent of cervical cancer and dysplasia. Thus, cervical cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines. Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results, with nearly 100% efficacy in preventing the development of persistent infections and cervical dysplasia. Questions remain, however, concerning the duration of protection, vaccine acceptability, and feasibility of vaccine delivery in the developing world. Screening recommendations might also be modified based on the longer-term follow-up data and cost-effectiveness considerations, but some level of screening is likely to be required for decades following the implementation of vaccine programs.
Unable to display preview. Download preview PDF.
- Bosch FX, de Sanjose S (2003) Chapter 1: HPVs and cervical cancer: burden and assessment of casuality. J Natl Cancer Inst Monogr 3–13Google Scholar
- Centers for Disease Control and Prevention (2004) Genital HPV infection—CDC Fact Sheet. Centers for Disease Control and Prevention, AtlantaGoogle Scholar
- Dubin G (2005) Enhanced immunogenicity of a candidate HPV 16/18 L1 VLP vaccine with novel ASO4 adjuvant in preteens/adolescents. Poster presentation, 45th ICAAC meeting, Washington, DC, December 2005Google Scholar
- Dubin G, Colau B, Zahat T, Quint W, Martin MT, Jenkins D (2005) Cross-protection against persistent HPV infection, abnormal cytology and CIN associated with HPV 16 and 18 related HPN types by a HPV 16/18 L1 VLP vaccine. 22nd International Papilloma Conference, Vancouver, Canada, April–May 2005Google Scholar
- FDA (2006) FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html. Cited 16 August 2006Google Scholar
- Giannini SL, Hanon E, Fourneau MA, Colau B, Suzich J, Losonsky G et al (2005) Superior immune response induced by vaccination with HPV 16/18 L1 VLP formulated with AS04 compared to aluminum salt only formulation. Poster presentation, 4th Annual American Association for Cancer Research (AACR) International Conference on Frontiers in Cancer Prevention Research, Baltimore, MD, September 5, 2005Google Scholar
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364:1757–1765PubMedCrossRefGoogle Scholar
- Lowy DR, Frazer IH (2003) Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 111–116Google Scholar
- Pratt D, Goldenthal K, Gerber A (2001) Preventive HPV vaccines. FDA Advisory Committee, Vaccines and Related Biological Products meeting, November 28–29, 2001Google Scholar
- Richardson H, Kelsall H, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 6:485–490Google Scholar
- Skjeldestad FE et al (2005) Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Infectious Disease Society of America 43rd Annual Meeting, San Francisco, CA, October 7, 2005; Abstract LB-8aGoogle Scholar
- Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 30[Suppl 1]:S1–S15Google Scholar
- Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278PubMedCrossRefGoogle Scholar